Nautilus Biotechnology (NAUT) Research & Development (2020 - 2026)

Nautilus Biotechnology has disclosed Research & Development across 7 years of filings, most recently posting $9.7 million for Q1 2026.

• Research & Development for Q1 2026 came in at $9.7 million, down 15.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.3 million (down 19.97% YoY), and the FY2025 annual result was $41.1 million, down 18.56% from the prior year.
• Research & Development came in at $9.7 million for Q1 2026 at Nautilus Biotechnology, up from $9.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $12.9 million in Q1 2024 to a low of $8.9 million in Q2 2022.
• The 5-year median for Research & Development is $10.9 million (2023), against an average of $11.0 million.
• Across the five-year window, Research & Development surged 99.75% in 2022 and dropped 25.33% in 2025, its largest moves.
• Nautilus Biotechnology's Research & Development stood at $9.6 million in 2022, then surged by 30.03% to $12.5 million in 2023, then increased by 2.86% to $12.8 million in 2024, then decreased by 25.33% to $9.6 million in 2025, then gained by 1.38% to $9.7 million in 2026.
• The last three Research & Development figures came in at $9.7 million (Q1 2026), $9.6 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.